Inflammatory biomarkers and statins

Drugs of Today

Volumn 41, Issue 3, 2005, Pages 171-177

  Blanco Colio, Luis Miguel ^a   Tuñón, José ^a   Martín Ventura, José Luis ^a   Egido, Jesus ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULE; CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG INDICATION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATORY DISEASE; PATHOGENESIS; REVIEW;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 18244361815     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.3.892522     Document Type: Review

References (42)

1. Mortensen, R.F. C-reactive protein, inflammation, and innate immunity. Immunol Res 2001, 24: 163-176.
2. Ridker, P.M. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103: 1813-18.
3. Ridker, P.M., Rifai, N., Pfeffer, M.A. et al. Inflammation, pravastatin, and the risk of cholesterol levels. Circulation 1998, 98: 839-44.
4. Ridker, P.M., Rifai, N., Clearfield, M. etal. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344: 1959-65.
5. Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA. 2001, 285: 1711-18.
6. Albert, M.A., Danielson, E., Rifai, N., Ridker, P.M. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE). A randomized trial and cohort study. JAMA 2001, 286: 64-70.
7. Taylor, A.J., Kent, S.M., Flaherty, P.J. et al. ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima media/thickness. Circulation 2002, 106: 1055-60.
8. Nissen, S.E., Tuzcu, E.M., Schoenhagen, P. et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352: 29-38.
9. Ridker, P.M., Cannon, C.P., Morrow, D. et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352: 20-8.
10. Gómez-Gerique, J.A., Ros, E., Oliván, J. et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis. 2002, 162:245-51.
11. Mach, F., Schonbeck, U., Sukhova, G.K. et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997, 94: 1931-6.
12. Schonbeck, U., Libby, P. CD40 signaling and plaque instability. Circ Res 2001, 89:1092-103.
13. Bavendiek, U., Libby, P., Kilbride, M. et al. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 2002, 277: 25032-9.
14. Lindmark, E., Tenno, T., Siegbahn, A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000, 20: 2322-8.
15. Lutgens, E., Gorelik, L., Daemen, M.J. et al. Requirement for CD 154 in the progression of atherosclerosis. Nat Med 1999, 5: 1313-16.
16. Schonbeck, U., Varo, N., Libby, P. et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001, 104:2266-8.
17. Garlichs, C.D., Eskafi, S., Raaz, D. et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001, 86: 649-55.
18. Heeschen, C., Dimmeler, S., Hamm, C.W. et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348: 1104-11.
19. Hwang, Y.S., Tsai, W.C., Lu, YH., Lin, C.C., Chen, YF. Effect of atorvastatin on the expression of CD40L and P-selectin in patients with hypercholesterolemia. Am J Cardiol 2004, 94: 364-6.
20. Semb, A.G., van Wissen, S., Ueland, T. et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 2003, 41:275-9.
21. Kinlay, S., Schwartz, G.G., Olsson, A.G. et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study. Circulation 2004, 110: 386-91.
22. Ridker, P.M., Hennekens, C.H., Roitman-Johnson, B. et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351: 88-92.
23. Hackman, A., Abe, Y., Insull, W. Jr. et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996, 93: 1334-8.
24. Hwang, S.J., Ballantyne, C.M., Sharrett, AR. et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997, 96: 4219-25.
25. Ridker, P.M., Buring, J.E., Rifai, N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001, 103: 491-5.
26. Blankenberg, S., Rupprecht, H.J., Bickel, C. et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104: 1336-42.
27. Mulvihill, N.T., Foley, J.B., Murphy, R.T. et al. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001, 85: 623-7.
28. Malik, I., Danesh, J., Whincup, P. et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and metaanalysis. Lancet 2001, 358: 971-6.
29. Romano, M., Mezzetti, A., Marulli, C. et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investing Med 2000, 48: 183-9.
30. Nawawi, H., Osman, N.S., Yusoff, K., Khalid, B.A. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res 2003, 35: 479-85.
31. Jilma, B., Joukhadar, C., Derhaschnig, U. et al. Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia. Clin Sci 2003, 104: 189-193.
32. Inoue, S., Egashira, K., Ni, W. et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilisation of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002, 106: 2700-6.
33. de Lemos, J.A., Morrow, D.A., Sabatine, M.S. et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003, 107: 690-5.
34. Xu, Z.M., Zhao, S.P., Li, Q.Z., Nie, S., Zhou, H.N. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 2003, 338: 17-24.
35. Rezai-Majd, A., Maca, T., Bucek, R.A. et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002, 22: 1194-9.
36. Cesari, M., Penninx, B.W., Newman, A.B. et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108: 2317-22.
37. Volpato, S., Guralnik, J.M., Ferrucci, L. et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: The Women's Health and Aging Study. Circulation 2001, 103: 947-53.
38. Nawawi, H., Osman, N.S., Annuar, R., Khalid, B.A., Yusoff, K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 2003, 169: 283-291.
39. Marz, W., Winkler, K., Nauck, M., Bohm, B.O., Winkelmann, B.R. Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). Am J Cardiol 2003, 92: 305-8.
40. French, L.E., Hahne, M., Virad, I. et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996, 133: 335-43.
41. Sata, M., Walsh, K. TNF-α regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998, 4: 415-20.
42. Blanco-Colio, L.M., Martin-Ventura J.L., Sol, J.M., Diaz, C., Hernandez, G., Egido, J. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol 2004, 43: 1188-94.